Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1

Myeloma highlights from ASH 2019

Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results

FLT3-inhibition in infants with acute lymphoblastic leukaemia

Chronic lymphocytic leukaemia highlights from ASH 2019

Benefits of apixaban among venous thromboembolism patients with active cancer

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-negative ALL

Updates on REGN1979 in R/R B-cell non-Hodgkins lymphoma

Eligibility criteria in acute myeloid leukaemia clinical trials

Azacitidine plus nivolumab in older adults with AML or MDS